KIMS Hospitals Q4 FY'26 Earnings Call Transcript Released
KIMS Hospitals released its Q4 FY'26 earnings call transcript. Q4 revenue reached ₹1,084 crore (up 35.3% YoY), with EBITDA at ₹216 crore (up 6.8% YoY). FY'26 revenue was ₹3,931 crore (up 28.2% YoY), with EBITDA at ₹828 crore (up 1.6% YoY). The company plans a ₹1,500 crore QIP to reduce debt and fund expansions. New units are contributing to growth, with ongoing focus on operational efficiency and market penetration.
The announcement provides detailed financial results for Q4 and FY'26, along with strategic updates on expansions and capital raising (QIP). This information is crucial for investors and analysts to assess the company's performance and future outlook, thus having a medium impact on market perception.
The announcement is a transcript of an earnings call, which provides factual information about financial performance and strategic discussions. While there are positive growth figures, there are also challenges mentioned, such as declining PAT and EBITDA margins in Q4 FY'26, and initial losses in new units. The overall tone is informative rather than strongly positive or negative.
Krishna Institute of Medical Sciences Limited (KIMS Hospitals) has released the transcript of its earnings conference call with investors and analysts, held on Monday, May 18, 2026, at 09:30 AM IST. The call, hosted by IIFL Capital, featured insights from Founder & Managing Director Dr. Bhaskar Rao Bollineni, Executive Director & CEO Dr. Abhinay Bollineni, and CFO Mr. Sachin Salvi.
During the call, the management reported Q4 FY'26 highlights including a total revenue of ₹1,084 crore, a year-on-year growth of 35.3%, and EBITDA of ₹216 crore, a 6.8% year-on-year increase. EBITDA margin stood at 19.9%. For the full fiscal year FY'26, total revenue grew by 28.2% year-on-year to ₹3,931 crore, while EBITDA was ₹828 crore, a 1.6% year-on-year increase. PAT for FY'26 was ₹242 crore against ₹415 crore in FY'25. Consolidated revenue from operations for Q4 FY'26 was ₹1,075 crore, a 34.8% year-on-year growth. Operational highlights for Q4 FY'26 included a 13.7% year-on-year growth in average revenue per operating bed and a 17.9% year-on-year increase in IP volumes.
The company discussed its expansion strategy, opening new hospitals and fertility centers in various locations including Hyderabad, Guntur, Thane, Sangli, Bangalore, and Kerala. The management also addressed the financial performance of new units, noting an initial drag on profitability due to heavy expenditure, but expressed confidence in their future turnaround. Discussions also covered the planned QIP of ₹1,500 crore, intended to retire debt and fund future greenfield projects and potential acquisitions. The company is exploring expansion in its home markets of Karnataka, Kerala, Andhra, and Telangana. The Kondapur facility in Hyderabad is set to transition to a new 800-bed hospital starting in June 2026, with phased commissioning. The management also addressed challenges related to insurance empanelments, particularly for new hospitals, and provided updates on ARPOB and occupancy rates in various geographies.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.